Core Insights - Klotho Neurosciences, Inc. is evaluating the acquisition of complementary technologies to enhance brain function, organ health, and longevity [1][2] - The company aims to expand its focus beyond neurodegenerative diseases to include technologies that support healthy aging and reduce age-related diseases [2][3] Company Developments - Klotho is currently manufacturing and developing clinical treatments KLTO-101 and KLTO-202, while also exploring additional therapies for healthy aging [3] - The Klotho gene is identified as a "master gene" linked to aging and longevity, with its levels declining with age, contributing to various age-related disorders [3][4] Scientific Focus - The company is assembling a team to identify key longevity indicators, evaluating genes and proteins such as alpha-Klotho, beta-Klotho, and FOXO3 [4] - The mission is to develop complementary assets to delay the onset of age-related diseases affecting the brain, heart, kidneys, liver, bone, and muscle [4] Company Profile - Klotho Neurosciences, Inc. specializes in innovative, disease-modifying cell and gene therapies derived from the human Klotho gene, targeting neurodegenerative and age-related disorders [4] - The company’s portfolio includes proprietary cell and gene therapy programs utilizing DNA and RNA as therapeutics [4]